文献速递临床免疫分子诊断

VioOne HIV补充检测试剂盒的性能评估

Evaluation of the VioOne HIV profile supplemental assay.
PubMed 文献 · J Clin Microbiol · 2024-01-11

多中心研究评估了Avioq VioOne HIV Profile补充检测试剂盒两个版本的临床性能,并与Geenius HIV 1/2补充检测试剂盒的公开性能参数进行比较。两个版本均与Geenius表现相当,其中版本2(去除HIV-2 p27抗体检测)在重现性、特异性和敏感性上优于前一版本,为临床实验室提供了额外的HIV检测选择。

要点

  • VioOne补充检测试剂盒两个版本与Geenius HIV 1/2补充检测试剂盒性能相当。
  • 版本2(无HIV-2 p27抗体检测)的重现性、特异性和敏感性优于版本1。
  • VioOne试剂盒为实验室提供了改善和扩展HIV检测能力的额外选项。

核心结论

  • VioOne HIV补充检测试剂盒与Geenius HIV 1/2补充检测试剂盒性能相当,其中版本2在重现性、特异性和敏感性上优于版本1。
  • 该试剂盒为临床实验室改善和扩展HIV检测能力提供了额外选择。

研究设计与样本

  • 多中心研究,评估Avioq VioOne HIV Profile补充检测试剂盒两个独立版本的临床性能。
  • 性能与Geenius HIV 1/2补充检测试剂盒(当前HIV补充检测的金标准)产品说明书公开参数进行比较。

主要发现

  • 两个VioOne版本与Geenius HIV 1/2补充检测试剂盒的性能参数相当。
  • 版本2(缺少HIV-2 p27抗体检测)相比前一版本展现出更好的重现性、特异性和敏感性。

临床怎么用

  • 实验室可考虑将VioOne HIV补充检测试剂盒作为HIV补充确认和HIV-1/HIV-2抗体分型的额外选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

HIV is an ongoing global epidemic with estimates of more than a million new infections occurring annually. To combat viral spread, continuous innovations in areas including testing and treatment are necessary. In the United States, the Centers for Disease Control and Prevention recommend that laboratories follow an HIV testing algorithm that first uses a US Food and Drug Administration approved immunoassay to detect antibodies to HIV-1 or HIV-2 as well as HIV-1 p24 antigen in serum or plasma samples. An initially reactive specimen is tested by a supplemental assay for confirmation and to differentiate antibodies to HIV-1 or HIV-2. There are few Food and Drug Administration (FDA)-approved supplemental differentiation tests currently available. A multicenter investigation was conducted to determine the clinical performance for two independent versions of the Avioq VioOne HIV Profile Supplemental Assay (Avioq, Inc., Research Triangle Park, NC). The performance of both assay versions compared favorably with the performance parameters for the Geenius HIV 1/2 Supplemental Assay as published in that assay package insert (Bio-Rad Laboratories, Hercules, CA), the current gold standard for HIV supplemental testing. When comparing the two VioOne assays, version 2 (lacking HIV-2 p27 antibody detection) demonstrated improved reproducibility, specificity, and sensitivity as compared to its predecessor. IMPORTANCE We evaluated the reproducibility, sensitivity, and specificity data for two versions of the VioOne HIV Profile Supplemental Assay and compared these results back to similar results for the Geenius HIV 1/2 Supplemental Assay that are publicly available. Our study concluded that the VioOne HIV Profile Supplemental Assay compared favorably with the Geenius HIV 1/2 Supplemental Assay, thus providing an additional option for clinical laboratories to improve and expand their HIV testing capabilities.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Franz BJ, Register H, Sullivan V, et al. Evaluation of the VioOne HIV profile supplemental assay. J Clin Microbiol. 2024. PMID: 38206000. doi:10.1128/jcm.00836-23

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。